首页 › 基金 › SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC › BBIO

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 对 BBIO 的持仓历史

BRIDGEBIO PHARMA INC · 医疗保健

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 在 Q3 2026 的 13F 申报中披露持有 BBIO(BRIDGEBIO PHARMA INC)450,000 股,市值约 US$29.6M,约占其申报组合的 0.88%,在其申报持仓中市值排名第 34 位。 SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 最近 7 个申报季度中有 7 个季度披露了 BBIO 持仓,最早可追溯至 Q1 2025。

最新持仓 (Q3 2026)450.00K 股
申报持仓市值$29.61M
组合权重0.88%
首次申报Q1 2025
最近变动减持
更新于2026-11-16

最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 对 BBIO 的持仓演变

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 于 Q1 2025 首次披露 BBIO 持仓:1,129,592 股(约 US$39.0M)。 该持仓在 Q4 2025 达到峰值 813,794 股,市值约 US$62.2M。 在 7 次申报中,SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 3 次增持、3 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 450,000 股、市值约 US$29.6M,环比减持 -171,125 股。。 持仓曾出现大幅变动:Q2 2025 减持约 33% (随后一个季度股价上涨 20%)、Q1 2026 减持约 82% (随后一个季度股价基本持平)、Q2 2026 增持约 314% (随后一个季度股价下跌 12%)。

逐季持仓明细

季度股数金额变化
Q1 2025 1.13M $39.05M 新进
Q2 2025 757.75K $32.72M 减持
Q3 2025 806.71K $41.90M 增持
Q4 2025 813.79K $62.25M 增持
Q1 2026 150.00K $11.14M 减持
Q2 2026 621.12K $46.26M 增持
Q3 2026 450.00K $29.61M 减持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 BBIO 与 13F 数据

BBIO(BRIDGEBIO PHARMA INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 BBIO,申报仓位最大的包括:Jupiter Topco LLC (US$1.05B), 骏利亨德森集团 (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 BBIO 的基金

查看 BBIO 的全部基金持有人 →

常见问题

How long has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC held BBIO?

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's current position in BBIO?

As of Q3 2026, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds 450.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $29.61M, representing 0.88% of its reported portfolio and ranking #34.

Has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC been buying or selling BBIO?

In the latest 13F filing (Q3 2026), SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC reduced its position in BBIO. The position peaked in Q4 2025 at 813.79K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, 骏利亨德森集团, FARALLON CAPITAL MANAGEMENT, L.L.C., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.